IMVT — Immunovant Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapNeutral

Annual balance sheet for Immunovant, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	—	—	—	—	—
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash
Cash and Short Term Investments	0.325	101	400	494	377
Net Total Accounts Receivable
Net Total Receivables	—	3.04	0.548	12.9	0.885
Prepaid Expenses
Total Other Current Assets
Total Current Assets	0.405	109	409	513	404
Net Property, Plant And Equipment	—	0.065	3.48	2.63	1.5
Other Long Term Assets
Total Assets	0.405	109	412	516	406
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	0.38	15.3	18.8	44.5	43.3
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	0.38	15.3	21	45.7	43.3
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	0.025	94.1	391	470	362
Total Liabilities & Shareholders' Equity	0.405	109	412	516	406
Total Common Shares Outstanding